All articles tagged with #unitedhealth
Major insurers are discontinuing unprofitable Medicare Advantage plans, forcing approximately five million beneficiaries to switch coverage for 2027. This shift is expected to raise out-of-pocket costs for prescriptions and medical care, particularly in rural areas where options are vanishing.
As 2027 open enrollment begins, approximately 5 million Americans are forced to switch Medicare Advantage plans due to widespread insurer withdrawals. Major carriers like UnitedHealth and Centene are exiting unprofitable markets, particularly in rural areas, leaving some counties with no coverage options. While average premiums may drop, out-of-pocket costs and prescription prices are rising, prompting experts to warn of increased financial hardship for older adults.
UnitedHealth said it will stop requiring approvals for a range of tests, surgeries and therapies, using AI to automate or eliminate prior authorizations for items like echocardiograms and certain outpatient services. The move aims to cut required authorizations by nearly a third this year and speed access to care, noting that prior authorizations currently apply to about 2% of services and most approvals occur within 24 hours. The policy shift signals how AI could reshape the financial side of healthcare across Medicare, Medicaid and employer plans.
Morgan Stanley upgrades UnitedHealth (UNH) to Top Pick ahead of its Q1 results, citing clearer Medicare Advantage rate guidance, ongoing MA margin improvement, an Optum Health turnaround, and potential AI-driven efficiencies. A Q1 miss or beat is expected to be largely in line with expectations, with analysts eyeing tangible margin gains in 2027–2028 and a stronger stock trajectory if results align. The firm’s price target is $375 amid a broader Street consensus of Strong Buy with roughly 13% 12‑month upside.
Markets were mixed as 3M’s cautious full-year guidance drew attention despite a Q1 beat, while UnitedHealth topped estimates and raised its outlook; European and Asia-Pacific equities rose on hopes for Iran peace talks, and Apple announced John Ternus as CEO as Hong Kong saw a notable IPO move, signaling ongoing market activity.
Despite a Q4 EBIT shortfall driven by weaker Optum Health margins and higher opex, Goldman Sachs maintains a Buy rating on UnitedHealth with a $421 target and says the 2026 EPS guidance of $17.75+ is on track with Street expectations. The analyst notes margin improvements in Optum (about 5.1%) and a company-wide operating margin guide of ~3.2%, amid Medicare funding pressure. The stock has fallen roughly 20% to around $282 and sits near a 52-week low, though the note emphasizes the path to margin recovery and long-term upside.
The Trump administration proposed Medicare insurer payment rates that were lower than analysts expected, triggering a sharp selloff in stocks of UnitedHealth Group, Humana, and CVS Health as investors priced in tighter reimbursements.
UnitedHealth beat Q4 earnings modestly ($2.11 vs. $2.10) but issued soft 2026 revenue guidance of just over $439 billion (about a 2% decline from 2025) due to divestitures, a planned U.S. membership reduction, and a roughly $6 billion revenue hit from Medicare’s new V28 coding system. The company aims a domestic-focused turnaround with higher prices, trimmed benefits, and transparency, targeting a 2026 medical benefit ratio of about 88.8% (around 50 bps wide of error), improving from 89.1% in 2025.
UnitedHealth Group pledged to eliminate and rebate profits earned from the Affordable Care Act marketplace in 2026, aiming to ease affordability as enhanced ACA subsidies expire and faces scrutiny ahead of House hearings. The move would affect about 1 million UnitedHealth ACA customers, with details being coordinated with the administration.
Bernstein analyst Lance Wilkes designates UnitedHealth Group (UNH) as his top healthcare stock for 2026, keeping an Outperform rating with a $444 target as margins in Medicare Advantage/Medicaid are expected to recover. He expects earnings growth to resume as UNH exits unprofitable businesses and weighs the potential separation of UnitedHealthcare and Optum, with Optum viewed as a long‑term growth driver. Bernstein sees roughly 33% upside from current levels, while the broader market consensus remains bullish with a target near $398 (~19% upside).
Billionaire hedge fund manager David Tepper sold major stakes in stocks like Intel and UnitedHealth, and is now heavily investing in Whirlpool, signaling a contrarian move towards recovery-focused investments amid market fluctuations.
The stock market rose today following a government shutdown deal, with major indexes gaining, while UnitedHealth dropped after Trump's comments on health insurers. Nvidia and Tesla stocks rallied, and the Senate passed a short-term funding bill, though the shutdown may delay key economic data releases.
UnitedHealth Group is profiting from the open enrollment period amid political deadlock over extending premium tax credits, highlighting how insurers benefit regardless of policy outcomes while consumers face rising costs.
UnitedHealth Group beat earnings expectations with a $2.92 EPS but missed revenue targets and saw a 50% drop in operating income, driven by challenges in managing medical costs and Medicare funding. The company's UnitedHealthcare segment grew strongly, while Optum's growth slowed, raising concerns about future margins. Despite raising full-year guidance, cautious outlooks remain as management navigates ongoing headwinds, with shares rising pre-market on positive earnings and Berkshire Hathaway's new investment.
Stock futures rose ahead of the Federal Reserve's policy meeting, with the Dow up 0.5% and UnitedHealth jumping 3.5% after strong earnings, as investors await the Fed's rate decision and guidance.